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Surgical TechniquesTransapical JenaValve in a degenerated Freedom
SOLO bioprosthesisLaurens Willem Wollersheim, MD, Riccardo Cocchieri, MD, Petr Symersky, MD, PhD, and
Bas A. de Mol, BA, MD, PhD, Amsterdam, The NetherlandsDegeneration of an aortic bioprosthesis is a complication
often requiring high-risk surgical reintervention. Tran-
scatheter aortic valve implantation (TAVI) provides an
alternative to high-risk surgery. However, TAVI for a degen-
erated stentless bioprosthesis becomes more perilous
because of the lack of support of a stent and the changed
landmarks of the aortic root. Furthermore, the supra-
annular implantation technique for the stentless Freedom
SOLO (Sorin Group, Milan, Italy) bioprosthesis may in-
crease the risk for coronary occlusion after deployment
because of the reduced distance between the neoannulus
and the coronary ostia. In this setting, the use of the Jena-
Valve (JenaValve Technology, GmbH,M€unchen, Germany)
could reduce the risk of coronary ostium obstruction
because of the specific design of this device. To illustrate
this clinical problem, we present the first reported case after
successful transcatheter valve-in-valve implantation of a
JenaValve in a degenerated Freedom SOLO.FIGURE 1. Reconstruction of the aortic root with measurements of the
distance between the coronary ostia and the supra-annular Freedom
SOLO (Sorin Group, Milan, Italy).CLINICAL SUMMARY
An 86-year-old woman presented with progressive dys-
pnea on exertion. Her medical history included hyperten-
sion, chronic obstructive pulmonary disease, and aortic
valve replacement (Freedom SOLO 23 mm) for aortic
valve stenosis 7 years previously. Transthoracic echocardi-
ography showed severe aortic valve stenosis with a
maximum gradient of 103 mm Hg and a mean gradient of
65 mm Hg over the Freedom SOLO, with an aortic valve
area of 0.6 cm2. The logistic European System for Cardiac
Operative Risk Evaluation score was 36.5%, and the Soci-
ety of Thoracic Surgeons score was 6.3%. The distance,
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The Journal of Thoracic and Cabetween the leaflets’ base and the coronary ostia was 10
mm and 9 mm for the right and left coronary ostia, respec-
tively. Because of the short distance between the coronary
ostia and the neoannulus of the Freedom SOLO, the Jena-
Valve was preferred to reduce the risk of coronary
occlusion.
Access to the left ventricular apex was achieved through
an anterolateral mini-thoracotomy in the fifth intercostal
space. Once the ideal muscular spot was identified, a double
Prolene suture with pledgets and an epicardial pacing lead
were placed. Balloon valvuloplasty was performed under
rapid pacing. A 25-mm JenaValve was positioned in the
Freedom SOLO, and the positioning feelers were released
and verified for anatomic orientation in the nadirs of each
of the 3 leaflets (Figure 2, A). Correct positioning was veri-
fied under fluoroscopy, and the lower part of the stent was
released. The leaflets of the Freedom SOLO were clipped
onto the JenaValve while the valve unfolded (Figure 2, B).
Subsequently, the upper part of the JenaValve was
completely deployed (Figure 2, C). Transesophageal echo-
cardiography showed good function of the JenaValve with a
Vmax of 3 m/s, a mean gradient of 16 mmHg, and an aorticrdiovascular Surgery c Volume 148, Number 2 741
FIGURE 2. A, Anatomic orientation with the released positioning feelers, positioned in the nadirs of the leaflets. B, Lower part of the JenaValve (JenaValve
Technology, GmbH, M€unchen, Germany) released. Leaflets are clipped. C, The completely deployed JenaValve without aortic regurgitation.
Surgical Techniquesvalve area of 1.2 cm2, and no paravalvular leakage or aortic
insufficiency. The postoperative period was uneventful. The
patient was discharged in good condition to a cardiology
unit in a regional hospital near her home on postoperative
day 6.
DISCUSSION
The Freedom SOLO is a stentless aortic bioprosthesis im-
planted supra-annularly using only 1 running suture line in
the sinuses of Valsalva. Early malfunction of a Freedom
SOLO is rare, with only 3 reported cases in the known liter-
ature.1-3 This is the first reported case in which the risk for
surgical reintervention was deemed too high and TAVI was
found to be an attractive alternative. However, according to
the European guidelines, an elevated risk of coronary artery
ostium obstruction, in case of a short distance between the
aortic annulus and the coronary ostium, is an absolute
contraindication for TAVI.4 Al-Lamee and colleagues5 sug-
gest that the height of coronary ostia shorter than 10 mm
from the base of the aortic valve leaflets should be an overall
contraindication for TAVI, to prevent coronary arterial oc-
clusion We believe that this risk could be attenuated
because of the specific design of the JenaValve. The Jena-
Valve is a self-deploying nitinol prosthesis with an
anchoring mechanism that resembles a 3-foil paperclip
and grasps each of the leaflets. For deployment, 3 feelers
are first positioned in each of the 3 nadirs of the leaflets, af-
ter which the lower part of the fixation mechanism clasps742 The Journal of Thoracic and Cardiovascular Surgthe internal side of the aortic valve cusps for anchoring.
This allows anatomically correct positioning, preventing
coronary ostium obstruction. Furthermore, because of the
active clip fixation, there could be a lower risk of valve
migration toward the coronary ostia during expansion of
the JenaValve compared with other transcatheter valves.
The minimal coronary height required for placement of
the JenaValve is 8 mm.CONCLUSIONS
We support the use of the JenaValve when a transcatheter
valve-in-valve implantation is required in a degenerated
Freedom SOLO to reduce the risk of coronary ostium
obstruction.References
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